Disorders of mitochondrial fatty acyl‐CoA β‐oxidation
The DOI matches its Crossref record; 180 of the 180 references it cites were found in a registry or an index.
Abstract
In recent years tremendous progress has been made with respect to the enzymology of the mitochondrial fatty acid β‐oxidation machinery and defects therein. Firstly, a number of new mitochondrial β‐oxidation enzymes have been identified, including very‐long‐chain acyl‐CoA dehydrogenase (VLCAD) and mitochondrial trifunctional protein (MTP). Secondly, the introduction of tandem MS for the analysis of plasma acylcarnitines has greatly facilitated the identification of patients with a defect in fatty acid oxidation (FAO). These two developments explain why the number of defined FAO disorders has increased dramatically, making FAO disorders the most rapidly growing group of inborn errors of metabolism. In this review we describe the current state of knowledge of the enzymes involved in the mitochondrial oxidation of straight‐chain, branched‐chain and (poly)unsaturated fatty acyl‐CoAs as well as disorders of fatty acid oxidation. The laboratory diagnosis of these disorders is described, with particular emphasis on the methods used to identify the underlying enzyme defect and the molecular mutations. In addition, a simple flowchart is presented as a guide to the identification of mitochondrial FAO‐disorders. Finally, treatment strategies are discussed briefly.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients afflicted with these disorders present with nonketotic hypoglycemia, muscle weakness, pronounced elevations in long chain acylcarnitines and systemic carnitine depletion [91].”
From Intramuscular triacylglycerol and insulin resistance: guilty as charged or wrongly accused? (2010) · cites this paper as [91]
Citations
Cites
Ciabarra, A., Sullivan, J., Gahn, L., Pecht, G., Heinemann, S., & Sevarino, K. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-10-06498.1995 · Cited by 1,233
(2008) · Encyclopedia of Molecular Pharmacology · doi:10.1007/978-3-540-38918-7_6838 · Cited by 648
Millington, D. S., Kodo, N., Norwood, D. L., & Roe, C. R. (1990) · Journal of Inherited Metabolic Disease · doi:10.1007/bf01799385 · Cited by 571 · cited 1×
“…clear, however, that tandem mass spectrometry is the method of choice for the analysis of acylcarnitines, especially since acylcarnitine proÐles can readily be determined not only in plasma or serum samples but also in blood spots (Millington et al 1990 ; Rashed et al 1995a,b ; Vreken et al 1999).”
Muscle Carnitine Palmityltransferase Deficiency and Myoglobinuria
DiMauro, S., & DiMauro, P. M. M. (1973) · Science · doi:10.1126/science.182.4115.929 · Cited by 477 · cited 2×
“Schaefer and coworkers (1996) described three adult patients from the same family with symptoms of recurrent exercise-induced rhabdomyolysis mimicking adult-type CPT2 deÐciency (DiMauro and DiMauro 1973) except that these patients had an associated peripheral neuropathy.”
BackgroundRashed, M. S., Ozand, P. T., Bucknall, M. P., & Little, D. (1995) · Pediatric Research · doi:10.1203/00006450-199509000-00009 · Cited by 342 · cited 2×
“The proÐle of acylcarnitines in plasma obtained by tandem MS is unique and speciÐc for MCAD deÐciency characterized by elevated concentrations of together with elevated concentrations ofC8-carnitine and (Chace et al 1997 ; Rashed et al 1995b ; Vreken etC6-, C10- C10>1-acylcarnitine al 1999).”
BackgroundUchida, Y., Izai, K., Orii, T., & Hashimoto, T. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)48391-3 · Cited by 339 · cited 9×
“It is now clear that the long-chain enzyme identiÐed by Schulz (1974) is in fact a constituent of the mitochondrial trifunctional protein (MTP) identiÐed by Hashimoto and coworkers (Uchida et al 1992).”
BackgroundInfluentialAndresen, B. S., Olpin, S., Poorthuis, B. J. H. M., Scholte, H. R., Vianey-Saban, C., Wanders, R., Ijlst, L., Morris, A., Pourfarzam, M., Bartlett, K., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302261 · Cited by 305 · cited 2×
“Since these reports in 1993, many additional VLCADdeÐcient patients have been described (Andresen et al 1996, 1999 ; Aoyama et al 1995a,b ; Brown-Harrison et al 1996 ; Largilliere et al 1995 ; Merinero et al 1996 ; Ogilvie et al 1994 ; Sluysmans et al 1997 ; Smelt et al 1998) including a series of…”
BackgroundSelf-citationChace, D. H., Hillman, S. L., Van Hove, J. L. K., & Naylor, E. W. (1997) · Clinical Chemistry · doi:10.1093/clinchem/43.11.2106 · Cited by 280 · cited 1×
“The proÐle of acylcarnitines in plasma obtained by tandem MS is unique and speciÐc for MCAD deÐciency characterized by elevated concentrations of together with elevated concentrations ofC8-carnitine and (Chace et al 1997 ; Rashed et al 1995b ; Vreken etC6-, C10- C10>1-acylcarnitine al 1999).”
BackgroundRashed, M. S., Bucknall, M. P., Little, D., Awad, A., Jacob, M., Alamoudi, M., Alwattar, M., & Ozand, P. T. (1997) · Clinical Chemistry · doi:10.1093/clinchem/43.7.1129 · Cited by 275
Medium–chain acyl-coenzyme A dehydrogenase deficiency: Clinical course in 120 affected children
Iafolla, A. K., Thompson, R. J., & Roe, C. R. (1994) · The Journal of Pediatrics · doi:10.1016/s0022-3476(94)70363-9 · Cited by 274
Research works printed but not linked: 1
- VredendaalPJ van denBergIET StroobantsAK Van DerADL MalingreHE BergerR(1999)Structural organisation of the human short‐chainL‐3‐hydroxyacyl‐CoA dehydrogenase gene.Mamm Genome(in press)..
Cited by
Items 101–200 of 260
Herrema, H., Derks, T. G. J., van Dijk, T. H., Bloks, V. W., Gerding, A., Havinga, R., Tietge, U. J. F., Müller, M. M., Smit, P. G. A., Kuipers, F., et al. (2008) · Hepatology · doi:10.1002/hep.22284 · Cited by 41
Hintz, S. R., Matern, D., Strauss, A. W., Bennett, M. J., Hoyme, H. E., Schelley, S. L., Kobori, J. A., Colby, C. E., Lehman, N. L., & Enns, G. M. (2002) · Molecular Genetics and Metabolism · doi:10.1006/mgme.2001.3282 · Cited by 39
Studies on the metabolic fate of n-3 polyunsaturated fatty acids
Ferdinandusse, S., Denis, S., Dacremont, G., & Wanders, R. J. A. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m300223-jlr200 · Cited by 36
Self-citationCassol, E., Misra, V., Morgello, S., Kirk, G., Mehta, S., & Gabuzda, D. (2015) · Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000551 · Cited by 39
Bastin, J. (2013) · Biochimie · doi:10.1016/j.biochi.2013.05.012 · Cited by 40
de Moraes, M. S., Guerreiro, G., Sitta, Â., Coelho, D. D. M., Manfredini, V., Wajner, M., & Vargas, C. R. (2019) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2019.108206 · Cited by 37
Maguolo, A., Rodella, G., Dianin, A., Nurti, R., Monge, I., Rigotti, E., Cantalupo, G., Salviati, L., Tucci, S., Pellegrini, F., et al. (2020) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2020.100632 · Cited by 38
“Mitochondrial fatty acid oxidation disorders (FAODs) are a heterogeneous group of genetic autosomal recessive diseases caused by the altered activity of the enzymes involved in the fatty acid transport and their oxidation in the mitochondria [3].”
BackgroundTamaoki, Y., Kimura, M., Hasegawa, Y., Iga, M., Inoue, M., & Yamaguchi, S. (2002) · Brain and Development · doi:10.1016/s0387-7604(02)00074-8 · Cited by 37
Endocrine and enzymatic shifts during insect diapause: a review of regulatory mechanisms
Izadi, H. (2025) · Frontiers in Physiology · doi:10.3389/fphys.2025.1544198 · Cited by 36
Antioxidant dysfunction: potential risk for neurotoxicity in ethylmalonic aciduria
Pedersen, C. B., Zolkipli‐Cunningham, Z., Vang, S., Palmfeldt, J., Kjeldsen, M., Stenbroen, V., Schmidt, S. P., Wanders, R. J. A., Ruiter, J. P. N., Wibrand, F., et al. (2010) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-010-9086-6 · Cited by 38
“Deficient SCAD enzyme activity leads to accumulation of butyryl-CoA, which is converted to ethylmalonic acid (EMA) (Hegre et al. 1959) and/or butyryl-carnitine (Coates et al. 1988; Wanders et al. 1999).”
BackgroundSelf-citationter Veld, F., Mueller, M., Kramer, S., Haussmann, U., Herebıan, D., Mayatepek, E., Laryea, M. D., Primaßin, S., & Spiekerkoetter, U. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006449 · Cited by 35
Ventura, F. V., Ruiter, J. P. N., IJlst, L., de Almeida, I. T., & Wanders, R. J. A. (2005) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2005.07.030 · Cited by 46
Self-citationImmonen, T., Turanlahti, M., Paganus, A., Keskinen, P., Tyni, T. A., & Lapatto, R. (2015) · Acta Paediatrica · doi:10.1111/apa.13313 · Cited by 35
Bakermans, A. J., van Weeghel, M., Denis, S. W., Nicolay, K., Prompers, J. J., & Houten, S. M. (2013) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-013-9604-4 · Cited by 35
“Patients with inborn errors of FAO may present with cardiac symptoms, including hypertrophic cardiomyopathy, arrhythmia and sudden death (Wanders et al 1999; Rinaldo et al 2002).”
BackgroundClinical and biochemical monitoring of patients with fatty acid oxidation disorders
Lund, A. M., Skovby, F., Vestergaard, H., Christensen, M., & Christensen, E. (2010) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-009-9000-2 · Cited by 34
“Disorders of mitochondrial fatty acid oxidation (FAO) are a group of clinically and biochemically heterogeneous disorders (Wanders et al. 1999; Rinaldo et al. 1998; Sim et al. 2002; Kompare and Rizzo 2008).”
BackgroundLohr, K., Pachl, F., Gholami, A. M., Geillinger, K. E., Daniel, H., Küster, B., & Klingenspor, M. (2016) · Physiological Reports · doi:10.14814/phy2.12988 · Cited by 36
“Fatty acid oxidative enzymes acyl-CoA dehydrogenases (ACADS and ACAD10), which catalyze the first dehydrogenation of fatty acids (Wanders et al., 1999), and propionyl-CoA carboxylase (PCCA), the substrate of which arises from odd-numbered chain fatty acids and branch-chained amino acids (Desviat et…”
BackgroundJager, E. A., Kuijpers, M. M., Bosch, A. M., Mulder, M. F., Rubio‐Gozalbo, M. E., Visser, G., de Vries, M., Williams, M., Waterham, H. R., van Spronsen, F. J., et al. (2019) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12102 · Cited by 34
Prenatal diagnosis of disorders of fatty acid transport and mitochondrial oxidation
Rinaldo, P., Studinski, A. L., & Matern, D. (2001) · Prenatal Diagnosis · doi:10.1002/1097-0223(200101)21:1<46::aid-pd984>3.0.co;2-c · Cited by 34
MCL-1 is a master regulator of cancer dependency on fatty acid oxidation
Prew, M. S., Adhikary, U., Choi, D. W., Portero, E. P., Paulo, J. A., Gowda, P., Budhraja, A., Opferman, J. T., Gygi, S. P., Danial, N. N., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111445 · Cited by 33
“observed in inborn errors of fatty acid metabolism (Wanders et al., 1999).”
Haas, D., Niklowitz, P., Hörster, F., Baumgartner, E. R., Prasad, C., Rodenburg, R. J., Hoffmann, G. F., Menke, T., & Okun, J. G. (2009) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-009-1150-8 · Cited by 33
“Human skin fibroblast culture Human skin fibroblast cultures were performed as previously described (Kolker et al. 2001; Wanders et al. 1999).”
MethodPrimaßin, S., Tucci, S., Herebıan, D., Seibt, A., Hoffmann, L., ter Veld, F., & Spiekerkoetter, U. (2010) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-010-9105-7 · Cited by 35
“Other enzymes, such as longchain acyl-CoA dehydrogenase (LCAD), have partly overlapping substrate specificities (C10–C16) (Wanders et al. 1999), but LCAD is not as highly expressed in most human tissues (Chegary et al. 2009).”
BackgroundPurevsuren, J., Fukao, T., Hasegawa, Y., Kobayashi, H., Li, H., Mushimoto, Y., Fukuda, S., & Yamaguchi, S. (2009) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2009.07.011 · Cited by 31
Kang, E., Kim, Y.-M., Kang, M., Heo, S., Kim, G.-H., Choi, I.-H., Choi, J., Yoo, H., & Lee, B. H. (2018) · BMC Pediatrics · doi:10.1186/s12887-018-1069-z · Cited by 33
Bleeker, J. C., Kok, I. L., Ferdinandusse, S., de Vries, M., Derks, T. G. J., Mulder, M. F., Williams, M., Rubio‐Gozalbo, M. E., Bosch, A. M., van den Hurk, D., et al. (2018) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12037 · Cited by 30
Self-citationFatty Acid Oxidation Disorders in a Chinese Population in Taiwan
Chien, Y., Lee, N., Chao, M., Chen, L.-C., Chen, L., Chien, C.-C., Ho, H., Suen, J.-H., & Hwu, W. (2013) · JIMD Reports · doi:10.1007/8904_2013_236 · Cited by 30
Kluge, S., Kühnelt, P., Block, A., Merkel, M., Gocht, A., Lukács, Z., Kohlschütter, A., & Kreymann, G. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000045201.10682.f6 · Cited by 30
Diebold, I., Schön, U., Horváth, R., Schwartz, O., Holinski-Feder, E., Kölbel, H., & Abicht, A. (2019) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2019.01.003 · Cited by 29
Bergmann, S. R., Herrero, P., Sciacca, R. R., Hartman, J. J., Rubin, P. J., Hickey, K. T., Epstein, S., & Kelly, D. P. (2001) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1012711009687 · Cited by 30
Normal carnitine levels in patients with chronic fatigue syndrome
Soetekouw, P. M. M. B. (2000) · The Netherlands Journal of Medicine · doi:10.1016/s0300-2977(00)00030-9 · Cited by 30
Rydzik, A. M., Chowdhury, R., Kochan, G. T., Williams, S. T., McDonough, M. A., Kawamura, A., & Schofield, C. J. (2014) · Chemical Science · doi:10.1039/c4sc00020j · Cited by 30
Shirao, K., Okada, S., Tajima, G., Tsumura, M., Hara, K., Yasunaga, S., Ohtsubo, M., Hata, I., Sakura, N., Shigematsu, Y., et al. (2010) · Human Genetics · doi:10.1007/s00439-010-0822-7 · Cited by 31
Chakrapani, A., Olpin, S. E., Cleary, M., Walter, J. H., Wraith, J. E., & BESLEY, G. T. N. (2000) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1026712719416 · Cited by 28
“Few cases of TFP de¢ciency (McKusick 600980 and 143450) have been studied and no common mutation has been found (Wanders et al 1999).”
BackgroundDisorders of Mitochondrial Fatty Acid Oxidation and Related Metabolic Pathways
Stanley, C. A., Bennett, M. J., & Mayatepek, E. (2006) · Springer eBooks · doi:10.1007/978-3-540-28785-8_13 · Cited by 28
Low expression of long-chain acyl-CoA dehydrogenase in human skeletal muscle
Maher, A. C., Mohsen, A.-W. A., Vockley, J., & Tarnopolsky, M. A. (2010) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2010.03.011 · Cited by 27
Tucci, S. (2017) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-017-0016-8 · Cited by 27
On-chip acidification rate measurements from single cardiac cells confined in sub-nanoliter volumes
Ges, I. A., Dzhura, I., & Baudenbacher, F. J. (2008) · Biomedical Microdevices · doi:10.1007/s10544-007-9142-7 · Cited by 27
“VLCAD is required to metabolize fatty acid, the preferred substrate of the heart (Wanders et al., 1999).”
BackgroundCecatto, C., Hickmann, F. H., Rodrigues, M. D. N., Amaral, A. U., & Wajner, M. (2015) · FEBS Journal · doi:10.1111/febs.13526 · Cited by 28
Birkebæk, N., Simonsen, H., & Gregersen, N. V. (2002) · Acta Paediatrica · doi:10.1111/j.1651-2227.2002.tb01674.x · Cited by 27
Comparison of catabolism rate of fatty acids to carbon dioxide in mice
Shibata, R., Gotoh, N., Kubo, A., Kanda, J., Nagai, T., Mizobe, H., Yoshinaga, K., Kojima, K., Watanabe, H., & Wada, S. (2012) · European Journal of Lipid Science and Technology · doi:10.1002/ejlt.201200164 · Cited by 26
Fluoromethylated derivatives of carnitine biosynthesis intermediates – synthesis and applications
Rydzik, A. M., Leung, I. K. H., Thalhammer, A., Kochan, G. T., Claridge, T. D. W., & Schofield, C. J. (2013) · Chemical Communications · doi:10.1039/c3cc47581f · Cited by 26
Heslegrave, A., & Hussain, K. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3134 · Cited by 25
Tajima, G., Sakura, N., Shirao, K., Okada, S., Tsumura, M., Nishimura, Y., Ono, H., Hasegawa, Y., Hata, I., Naito, E., et al. (2008) · Pediatric Research · doi:10.1203/pdr.0b013e318187cc44 · Cited by 25
“(7) reported their method of this type and suggested its superiority to conventional spectrophotometric assays of reduced electron acceptors and radioisotope-dependent methods.”
MethodMcCoin, C. S., Piccolo, B. D., Knotts, T. A., Matern, D., Vockley, J., Gillingham, M. B., & Adams, S. H. (2016) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-016-9915-3 · Cited by 26
“Mitochondrial fatty acid oxidation disorders (FAOD) are a family of inherited autosomal recessive disorders (Wanders et al 1999) whose patients suffer from a metabolic defect in fatty acid catabolism, with an estimated incidence of one in every 5000–10,000 births (Watson et al 2006).”
BackgroundCharacterization of l-aminocarnitine, an inhibitor of fatty acid oxidation
Chegary, M., Brinke, H. T., Doolaard, M., IJlst, L., Wijburg, F. A., Wanders, R. J. A., & Houten, S. M. (2008) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2007.11.001 · Cited by 24
Self-citationCecatto, C., Amaral, A. U., da Silva, J. C., Wajner, A., Schimit, M. D. O. V., da Silva, L. H. R., Wajner, S. M., Zanatta, Â., Castilho, R. F., & Wajner, M. (2018) · FEBS Journal · doi:10.1111/febs.14419 · Cited by 25
Altered Metabolic Flexibility in Inherited Metabolic Diseases of Mitochondrial Fatty Acid Metabolism
Tucci, S., Alatibi, K. I., & Wehbe, Z. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073799 · Cited by 25
Tajima, G., Sakura, N., Yofune, H., Nishimura, Y., Ono, H., Hasegawa, Y., Hata, I., Kimura, M., Yamaguchi, S., Shigematsu, Y., et al. (2005) · Journal of Chromatography B · doi:10.1016/j.jchromb.2005.06.043 · Cited by 24
Bernard, A., Rigault, C., Mazué, F., Borgne, F. L., & Demarquoy, J. (2008) · The Journals of Gerontology Series A · doi:10.1093/gerona/63.10.1027 · Cited by 28
Purevsuren, J., Fukao, T., Hasegawa, Y., Fukuda, S., Kobayashi, H., & Yamaguchi, S. (2008) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2008.06.013 · Cited by 24
Eichhorn, P., & Knepper, T. P. (2002) · Environmental Toxicology and Chemistry · doi:10.1002/etc.5620210101 · Cited by 24
Schwab, K. O., Ensenauer, R. E., Matern, D., Uyanık, G., Schnieders, B., Wanders, R. J. A., & Lehnert, W. (2003) · European Journal of Pediatrics · doi:10.1007/s00431-002-1035-4 · Cited by 24
“In contrast to isolated LCHAD deficiency [18, 22, 28 ], prognosis of early-onset MTP deficiency appears to be poor with most patients having died early in infancy [1, 2, 4, 5, 6, 9,14].”
Self-citationPaapstel, K., Kals, J., Eha, J., Tootsi, K., Ottas, A., Piir, A., & Zilmer, M. (2016) · IJC Metabolic & Endocrine · doi:10.1016/j.ijcme.2016.05.001 · Cited by 25
Mitochondrial peptide Mtln contributes to oxidative metabolism in mice
Averina, O. A., Permyakov, O. A., Emelianova, M. A., Grigoryeva, O. O., Gulyaev, M. V., Pavlova, O. S., Mariasina, S. S., Frolova, O., Kurkina, M. V., Baydakova, G., et al. (2022) · Biochimie · doi:10.1016/j.biochi.2022.09.009 · Cited by 22
Tong, M. K. H., Lam, C. W. K., Mak, T. W. L., Fu, M. Y. P., Ng, S.-H., Wanders, R. J. A., & Tang, N. L. S. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00139205 · Cited by 22
“The defective gene of VLCAD has been located to the short arm of chromosome 17 between bands P11.2 and P11.13105 [ 6 ].”
BackgroundSelf-citationAtsuzawa, K., Nakazawa, A., Mizutani, K., Fukasawa, M., Yamamoto, N., Hashimoto, T., & Usuda, N. (2010) · Histochemistry and Cell Biology · doi:10.1007/s00418-010-0752-4 · Cited by 23
“Inborn errors of metabolism in particular enzymes of the mitochondrial fatty acid b-oxidation system (Wanders et al. 1999) cause pathological changes in retinal pigment epithelium, as in the case of mitochondrial long chain 3-hydroxyacyl-CoA dehydrogenase, a subunit of trifunctional protein (Lawlor…”
Law, L.-K., Tang, N. L. S., Hui, J., Ho, C. S., Ruiter, J. P. N., Fok, T. F., Wanders, R. J. A., & Lam, C. W. (2007) · Clinica Chimica Acta · doi:10.1016/j.cca.2007.03.011 · Cited by 21
Self-citationIncreased lipolysis in LCHAD deficiency
Halldin, M., Forslund, A. H., von Döbeln, U., Eklund, C., & Gustafsson, J. (2006) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-006-0296-x · Cited by 23
Tyni, T. A., Pourfarzam, M., & Turnbull, D. M. (2002) · Pediatric Research · doi:10.1203/00006450-200207000-00013 · Cited by 25
“diagnostic during a stable phase of the disease (1).”
BackgroundOey, N. A., Ruiter, J. P. N., IJlst, L., Attié‐Bitach, T., Vekemans, M. J. J., Wanders, R. J. A., & Wijburg, F. A. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.05.088 · Cited by 20
Self-citationImmonen, T., Ahola, E., Toppila, J. P., Lapatto, R., Tyni, T. A., & Lauronen, L. (2015) · European Journal of Paediatric Neurology · doi:10.1016/j.ejpn.2015.10.009 · Cited by 18
“Mitochondrial b-oxidation of fatty acids is essential for energy production during fasting.(1) The most common mitochondrial fatty acid b-oxidation (FAO) defect in Finland is long-chain 3hydroxyacyl dehydrogenase (LCHAD) deficiency.”
BackgroundHuidekoper, H. H., Schneider, J., Westphal, T., Vaz, F. M., Durán, M., & Wijburg, F. A. (2006) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-006-0355-3 · Cited by 18
“Although it has been shown that patients may exhibit secondary carnitine deficiency (Touma et al 1992), routine L-carnitine supplementation in MCADD is controversial ( Walter 2003; Winter 2003).”
BackgroundSelf-citationSchulze-Bergkamen, A., Okun, J. G., Spiekerkoetter, U., Lindner, M. S., Haas, D., Kohlmüller, D., Mayatepek, E., Schulze‐Bergkamen, H., Greenberg, C. R., Zschocke, J., et al. (2005) · Pediatric Research · doi:10.1203/01.pdr.0000181378.98593.3e · Cited by 18
Peroxisomes in Dermatology. Part I
Smith, K. J., DiPreta, E. A., & Skelton, H. G. (2001) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/120347540100500308 · Cited by 19
Oxidative phosphorylation: Structure, function, and intermediary metabolism
Heales, S., Gegg, M. E., & Clark, J. B. (2002) · International review of neurobiology · doi:10.1016/s0074-7742(02)53003-8 · Cited by 18
D’Annibale, O., Koppes, E., Sethuraman, M., Bloom, K., Mohsen, A.-W. A., & Vockley, J. (2022) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12492 · Cited by 16
Lefort, B., Gouache, E., Acquaviva, C., Tardieu, M., Benoist, J., Dumas, J., Servais, S., Chevalier, S., Vianey‐Saban, C., & Labarthe, F. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.04.005 · Cited by 16
Treem, W. R. (2000) · Current Opinion in Pediatrics · doi:10.1097/00008480-200010000-00008 · Cited by 16
He, F., Li, H., Zhang, H., Wang, S., Xu, S., Li, C., Yang, Y., & Cui, R. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1019312 · Cited by 16
“Abbreviations: HADH, short-chain-L-3-hydroxyacyl-CoA dehydrogenase; TME, tumor microenvironment; FAO, fatty acid oxidation; TIICs, tumor-infiltrating immune cells; PTEN, phosphatase and tensin homolog; AKT, serine threonine kinase; EMT, epithelial-mesenchymal transition; TNF- α, tumor necrosis factor-α; IL-6, interleu…”
BackgroundInfluentialInvestigation of the child with an acute metabolic disorder
Cook, P. L., & Walker, V. (2011) · Journal of Clinical Pathology · doi:10.1136/jcp.2009.067884 · Cited by 17
Lang, T., & Hussain, K. (2013) · Advances in clinical chemistry · doi:10.1016/b978-0-12-800094-6.00006-6 · Cited by 21
Zhang, R.-N., Li, Y., Qiu, W., Ye, J., Han, L.-S., Zhang, H., Lin, N., & Gu, X. (2014) · World Journal of Pediatrics · doi:10.1007/s12519-014-0480-2 · Cited by 14
Diekman, E. F., van Weeghel, M., Wanders, R. J. A., Visser, G., & Houten, S. M. (2014) · The FASEB Journal · doi:10.1096/fj.14-250241 · Cited by 15
Self-citationUpdate on investigating hypoglycaemia in childhood
Lang, T. (2011) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/acb.2011.011012 · Cited by 17
Bouvier, D., Vianey‐Saban, C., Ruet, S., & Acquaviva, C. (2016) · JIMD Reports · doi:10.1007/8904_2016_22 · Cited by 13
Habib, A., Azize, N. A. A., Rahman, S. A., Yakob, Y., Suberamaniam, V., Nazri, M. I. B. A., Sani, H. A., Ch’ng, G.-S., Leong, H. Y., Olpin, S. E., et al. (2021) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2021.10.002 · Cited by 12
Froemming, M. K., & Sameš, D. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200502675 · Cited by 12
D’Annibale, O., Phua, Y. L., Land, C. V., Karunanidhi, A., Dorenbaum, A., Mohsen, A.-W. A., & Vockley, J. (2022) · Cells · doi:10.3390/cells11172635 · Cited by 11
Herrera-Olivares, A. M., Fernández-Luque, J. A., Paradas, C., Lucía, A., & Santalla, A. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00650 · Cited by 12
“Very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency (VLCADD, OMIM 201475) is an autosomal recessive disorder (Andresen et al., 1999; Wanders et al., 1999; Lindner et al., 2010) with an estimated incidence of 1 in 30,000–100,000 newborns (Tucci et al., 2014).”
BackgroundHunt, M. C., Ruiter, J. P. N., Mooyer, P. A. W., van Roermund, C. W. T., Ofman, R., IJlst, L., & Wanders, R. J. A. (2005) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2005.01447.x · Cited by 11
Self-citationCollier, T. L., Hwang, Y. C., Ramasamy, R., Sciacca, R. R., Hickey, K. T., Simpson, N. R., & Bergmann, S. R. (2002) · PubMed · Cited by 10
Enoyl thioester reductases—enzymes of fatty acid synthesis and degradation in mitochondria
Miinalainen, I. (2006) · Cited by 10
Specifications of the ACMG/AMP guidelines for ACADVL variant interpretation
Flowers, M., Dickson, A., Miller, M. J., Spector, E., Enns, G. M., Baudet, H., Pasquali, M., Racacho, L., Sadre-Bazzaz, K., Wen, T., et al. (2023) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2023.107668 · Cited by 9
Dowsett, L., Lulis, L., Ficicioglu, C., & Cuddapah, S. (2017) · International Journal of Neonatal Screening · doi:10.3390/ijns3020010 · Cited by 9
“, normal acylcarnitine profiles do not rule out CPT1A deficiency and mild fatty acid oxidation defects [11].”
BackgroundZhang, W., & Sang, Y. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-02088-6 · Cited by 11
Disorders of Mitochondrial Fatty Acid Oxidation and Ketone Body Metabolism
de Baulny, H. O., & Superti‐Furga, A. (2006) · Springer eBooks · doi:10.1007/3-540-28962-3_16 · Cited by 9
Metabolic cause of Reye-like syndrome
Bzdúch, V., Behúlová, D., Lehnert, W., Fabriciová, K., Kozak, L., Šalingová, A., Hrabincová, E., & Benedeková, M. (2001) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/bf03656507 · Cited by 9
Beattie, S. G., Goetzman, E. S., Tang, Q., Conlon, T. J., Campbell‐Thompson, M., Matern, D., Vockley, J., & Flotte, T. R. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1242 · Cited by 9
Quintana, L. P., & Crespo, P. G. S. (2001) · Anales de Pediatría · doi:10.1016/s1695-4033(01)77732-6 · Cited by 9
Guerra, I. M. S., Ferreira, H. B., Maurício, T., Pinho, M., Diogo, L. M., Moreira, S., Goracci, L., Bonciarelli, S., Melo, T., Domingues, P. M., et al. (2024) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12718 · Cited by 9
Zieger, M. V., Keeler, A. M., Flotte, T. R., & ElMallah, M. K. (2019) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12101 · Cited by 8
Non-Invasive Analysis of Human Liver Metabolism by Magnetic Resonance Spectroscopy
Jones, J. G. (2021) · Metabolites · doi:10.3390/metabo11110751 · Cited by 9
Wehbe, Z., Alatibi, K. I., Jellusova, J., Spiekerkoetter, U., & Tucci, S. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2019.08.001 · Cited by 8
Alberto, M., Yim, A., Lawrentschuk, N., & Bolton, D. M. (2023) · Cancers · doi:10.3390/cancers15020341 · Cited by 9
Fat oxidation defect presenting with overwhelming ketonuria
Wraige, E. (2002) · Archives of Disease in Childhood · doi:10.1136/adc.87.5.428 · Cited by 7
Goetzman, E. S., He, M., Nguyen, T. V., & Vockley, J. (2005) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2005.09.027 · Cited by 7
Cheillan, D., Cognat, S., Vianey‐Saban, C., Maire, I., & Dorche, C. (2004) · PubMed · Cited by 10
Principles of management of the more common metabolic disorders
Chakrapani, A., & Wraith, J. E. (2002) · Current Paediatrics · doi:10.1054/cupe.2001.0262 · Cited by 6
Understanding the impact of long-chain fatty acid oxidation disorders for patients and caregivers
Kruger, E., Voorhees, K. N., Thomas, N., Judge, M., Galla, J., Kung, J., & Rodríguez, D. (2022) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2022.100903 · Cited by 6
Zhao, Z., Bao, M., Ma, G., Liu, X., Xu, W., Sun, Z., Chen, H., & Zhu, M. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12007 · Cited by 6
Inborn Errors of Mitochondrial Fatty Acid Oxidation
Angdisen, J. J., Dasouki, M., & Ibdah, J. A. (2007) · Cambridge University Press eBooks · doi:10.1017/cbo9780511547409.034 · Cited by 6
Metadata
- Authors
- Wanders, R. J. A., Vreken, P., den Boer, M. E. J., Wijburg, F. A., Van Gennip, A. H., & IJlst, L.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- Departments of Clinical Chemistry Academic Medical Center, University of Amsterdam The Netherlands
- Corresponding author
- Wanders, R. J. A.
- Venue
- Journal of Inherited Metabolic Disease
- Publisher
- Wiley
- Published
- 1999-06
- Volume
- 22
- Issue
- 4
- Pages
- 442-487
- ISSN
- 0141-8955 (ISSN-L)
- 1573-2665
- OpenAlex
- W2147457396
- Cited by
- 257
- References
- 180
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 12 · 2023: 4 · 2022: 9 · 2021: 5 · 2020: 5 · 2019: 7 · 2018: 7 · 2017: 7 · 2016: 8 · 2015: 7 · 2014: 12 · 2013: 13 · 2012: 5
- FWCI
- 1.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Inherited Metabolic Disease (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Keywords
- fatty acid beta-oxidation disorders, inborn errors of metabolism, VLCAD, mitochondrial trifunctional protein, acylcarnitines, tandem mass spectrometry, branched-chain fatty acids, polyunsaturated fatty acids, enzyme defects, molecular diagnosis, treatment options
- MeSH terms
- Acyl Coenzyme A, Fatty Acids, Fatty Acids, Unsaturated, Humans, Lipid Metabolism, Inborn Errors, Mitochondria, Oxidation-Reduction, Prenatal Diagnosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.